Back to Atlas
APotentially durableStandard research/education caution
CMP-0122
Approved in limited indications; controlled
Stanozolol / Winstrol
Ergogenic / AAS
Lean strength, collagen/tendon-risk tradeoff, non-aromatizing anabolic effect
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- 17α-alkylated DHT-derived AAS
- Primary mechanism
- AR agonist; A:A ratio ~30:1
- Primary market use
- Hereditary angioedema history; performance misuse
Pharmacology
- Molecular weight (Da)
- 328.49
- Oral bioavailability
- Oral; injectable suspension also used
- Half-life
- ~9 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/historical
- Clinical status
- Approved in limited indications; controlled
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Kuhn table lists stanozolol/stanozol A:A ratio ~30.